Activation of cyclic GMP-dependent protein kinase (cGK) is an important event in the regulation of blood pressure and platelet function. Upstream signals are the generation of nitric oxide (NO) by NO syntheses and the subsequent rise in cyclic GMP levels mediated by NO-dependent guanylyl cyclases (GCs). The identification of new cGK activators by high throughput sreening (HTS) may lead to the development of a novel class of therapeutics for the treatment of cardiovascular diseases. Therefore, a homogeneous, nonradioactive assay for cGK activity was developed using a biotinylated peptide derived from vasodilator-stimulated phosphoprotein (VASP), a well-characterized natural cGK substrate. The phosphorylated peptide could be detected by a VASP-specific monoclonal phosphoserine antibody and a fluorescent detection system consisting of a europium-labeled secondary antibody and allophycocyanin (APC)-labeled streptavidin. Fluorescence resonance energy transfer (FRET) from europium to APC was detected in a time-resolved fashion (TR-FRET). Activation and inhibition constants for known substances determined by this new fluorescence-based assay correlated well with published results obtained by conventional radioactive cGK activity assays. The assay proved to be sensitive, robust, highly specific for cGK, and suitable for HTS in 96- and 384-well formats. This assay is applicable to purified enzymes as well as to complex samples such as human platelet extracts.
References
1.
Lohmann SM, Vaandrager AB, Smolenski A, et al: Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci1997;22:307-312.
2.
Eigenthaler M, Lohmann SM, Walter U, et al: Signal transduction by cGMP-dependent protein kinases and their emerging roles in the regulation of cell adhesion and gene expression. Rev Physiol Biochem Pharmacol1999;135:173-209.
3.
Hofmann F, Ammendola A, Schlossmann J: Rising behind NO: cGMP-dependent protein kinases. J Cell Sci2000;113:1671-1676.
4.
Ross R: Atherosclerosis an inflammatory disease. N Engl J Med1999;340:115-126.
5.
Garbers DL, Dubois SK: The molecular basis of hypertension. Annu Rev Biochem1999;68:127-155.
6.
Pfeifer A, Klatt P, Massberg S, et al: Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J1998;17:3045-3051.
7.
Massberg S, Sausbier M, Klatt P, et al: Increased adhesion and aggregation of platelets lacking cyclic guanosine 3′,5′-monophosphate kinase I. J Exp Med1999;189:1255-1264.
8.
Sausbier M, Schubert R, Voigt V, et al: Mechanisms of NO/cGMP-dependent vasorelaxation. Circ Res2000;87:825-830.
9.
Raitakari OT, Celermajer DS: Testing for endothelial dysfunction. Ann Med2000;32:293-304.
10.
Bauersachs J, Bouloumie A, Mulsch A, et al: Vasodilator dysfunction in aged spontaneously hypertensive rats: changes in NO synthase III and soluble guanylyl cyclase expression, and in superoxide anion production. Cardiovasc Res1998;37:772-779.
11.
Ruetten H, Zabel U, Linz W, et al: Downregulation of soluble guanylyl cyclase in young and aging spontaneously hypertensive rats. Circ Res1999;85:534-541.
12.
Oelze M, Mollnau H, Hofmann N, et al: VASP serine239-phosphorylation as a sensitive monitor of defective NO/cGMP signalling and endothelial dysfunction. Circ Res2000;87:999-1005.
13.
Reinhard M, Jarchau T, Reinhard K, et al: VASP in Kreis T, Vale R (eds): Guidebook to the Cytoskeletal and Motor Proteins. Oxford, England: Oxford University Press, 1999:168-171.
14.
Moncada S, Higgs EA: Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J1995;9:1319-1330.
15.
Ko FN, Wu CC, Kuo SC, et al: YC-1, a novel activator of platelet guanylate cyclase. Blood1994;84:4226-4233.
16.
Corbin JD, Francis SH: Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem1999;274:13729-13732.
17.
Soderling SH, Beavo JA: Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol2000;12:174-179.
18.
Soff GA, Cornwell TL, Cundiff DL, et al: Smooth muscle cell expression of type I cyclic GMP-dependent protein kinase is suppressed by continuous exposure to nitrovasodilators, theophylline, cyclic GMP, and cyclic AMP. J Clin Invest1997;100:2580-2587.
19.
Munzel T, Li H, Mollnau H, et al: Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. Circ Res2000;86:E7-E12.
20.
Hobbs AJ, Higgs A, Moncada S: Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol1999;39:191-220.
21.
Hertzberg RP, Pope AJ: High-throughput screening: new technology for the 21st century. Curr Opin Chem Biol2000;4:445-451.
22.
Roskoski R Jr: Assays of protein kinase. Methods Enzymol1983;99:3-6.
23.
Park YW, Cummings RT, Wu L, et al: Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence. Anal Biochem1999;269:94-104.
24.
McDonald OB, Chen WJ, Ellis B, et al: A scintillation proximity assay for the Raf/MEK/ERK kinase cascade: high-throughput screening and identification of selective enzyme inhibitors. Anal Biochem1999;268:318-329.
25.
Lehel C, Daniel-Issakani S, Brasseur M, et al: A chemiluminescent microtiter plate assay for sensitive detection of protein kinase activity. Anal Biochem1997;244:340-346.
26.
Coffin J, Latev M, Bi X, et al: Detection of phosphopeptides by fluorescence polarization in the presence of cationic polyamino acids: application to kinase assays. Anal Biochem2000;278:206-212.
27.
Cohen CB, Chin-Dixon E, Jeong S, et al: A microchip-based enzyme assay for protein kinase A. Anal Biochem1999;273:89-97.
28.
Braunwalder AF, Yarwood DR, Sills MA, et al: Measurement of the protein tyrosine kinase activity of c-src using time-resolved fluorometry of europium chelates. Anal Biochem1996;238:159-164.
29.
Kolb AJ, Kaplita PV, Hayes DJ, et al: Tyrosine kinase assays adapted to homogeneous time-resolved fluorescence. Drug Discov Today1998;3:333-342.
30.
Smolenski A, Bachmann C, Reinhard K, et al: Analysis and regulation of vasodilator-stimulated phosphoprotein serine 239 phosphorylation in vitro and in intact cells using a phosphospecific monoclonal antibody. J Biol Chem1998;273:20029-20035.
31.
Hemmila I, Webb S: Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications. Drug Discov Today1997;2:373-381.
Walter U, Miller P, Wilson F, et al: Immunological distinction between guanosine 3′:5′-monophosphate-dependent and adenosine 3′:5′-monophosphate-dependent protein kinases. J Biol Chem1980;255:3757-3762.
34.
Pohler D, Butt E, Meissner J, et al: Expression, purification, and characterization of the cGMP-dependent protein kinases I beta and II using the baculovirus system. FEBS Lett1995;374:419-425.
35.
Markert T, Vaandrager AB, Gambaryan S, et al: Endogenous expression of type II cGMP-dependent protein kinase mRNA and protein in rat intestine: implications for cystic fibrosis transmembrane conductance regulator. J Clin Invest1995;96:822-830.
36.
Kemp BE, Pearson RB, House CM: Pseudosubstrate-based peptide inhibitors. Methods Enzymol1991;201:287-304.
37.
Butt E, Abel K, Krieger M, et al: cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro and in intact human platelets. J Biol Chem1994;269:14509-14517.
38.
Haffner C, Jarchau T, Reinhard M, et al: Molecular cloning, structural analysis and functional expression of the proline-rich focal adhesion and microfilament-associated protein VASP. EMBO J1995;14:19-27.
39.
Butt E, van Bemmelen M, Fischer L, et al: Inhibition of cGMP-dependent protein kinase by (Rp)-guanosine 3′,5′-monophosphorothioates. FEBS Lett1990;263:47-50.
40.
Eigenthaler M, Nolte C, Halbrugge M, et al: Concentration and regulation of cyclic nucleotides, cyclic-nucleotide-dependent protein kinases and one of their major substrates in human platelets: estimating the rate of cAMP-regulated and cGMP-regulated protein phosphorylation in intact cells. Eur J Biochem1992;205:471-481.
41.
Pope AJ, Haupts UM, Moore KJ: Homogeneous fluorescence readouts for miniaturized high-throughput screening: theory and practice. Drug Discov Today1999;4:350-362.
42.
Grepin C, Pemelle C: High-throughput screening. Drug Discov Today2000;5:212-214.
43.
Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen1999;4:67-73.
44.
Butt E, Nolte C, Schulz S, et al: Analysis of the functional role of cGMP-dependent protein kinase in intact human platelets using a specific activator 8-para-chlorophenylthio-cGMP. Biochem Pharmacol1992;43:2591-2600.
45.
Beavo JA, Rogers NL, Crofford OB, et al: Effects of xanthine derivatives on lipolysis and on adenosine 3′,5′-monophosphate phosphodiesterase activity. Mol Pharmacol1970;6:597-603.
46.
Butt E, Eigenthaler M, Genieser HG: (Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. Eur J Pharmacol1994;269:265-268.
47.
Hidaka H, Kobayashi R: Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol1992;32:377-397.
48.
Dixon M: The graphical determination of Km and Ki. Biochem J1972;129:197-202.
49.
Smolenski A, Poller W, Walter U, et al: Regulation of human endothelial cell focal adhesion sites and migration by cGMP-dependent protein kinase I. J Biol Chem2000;275:25723-25732.
50.
Smolenski A, Burkhardt AM, Eigenthaler M, et al: Functional analysis of cGMP-dependent protein kinases I and 11 as mediators of NO/cGMP effects. Naunyn Schmiedebergs Arch Pharmacol1998;358:134-139.
51.
Burkhardt M, Glazova M, Gambaryan S, et al: KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem2000;275:33536-33541.
52.
Sundberg SA: High-throughput and ultra-high-throughput screening: solution- and cell-based approaches. Curr Opin Biotechnol2000;l1:47-53.
53.
Sekhar KR, Hatchett RJ, Shabb JB, et al: Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type I alpha, compared with type I beta, cGMP-dependent protein kinase. Mol Pharmacol1992;42:103-108.
